Use of Naltrexone–Bupropion in Persons With Overweight/Obesity and Symptoms of Depression: A Pooled Analysis
Authors' conclusion
NB-ER appears to be both safe and effective for weight loss when offered to patients with mild to moderate symptoms of depression.
Study context
- Population
- Individuals with overweight/obesity and mild to moderate symptoms of depression (baseline Inventory of Depressive Symptomatology-Self-Report score ≥ 14)4 trials pooled
- Participants
- 511 individuals
- Comparison
- NB-ER vs placebo
- Outcome
- Percent weight loss and changes in depression, plus safety (psychiatric adverse events, depressive symptom increases, suicidal ideation)
- Follow-up
- 56 weeks
Methodological details4 double-blind, placebo-controlled trials, multiple imputation, intention-to-treat
- 4 double-blind, placebo-controlled trials
- Multiple imputation
- Intention-to-treat
Pooled result
As reported in the abstract
Percent weight loss
P = 0.003
Further pooled results
| Outcome | NB-ER | Placebo |
|---|---|---|
| Change in depressionCo-primary outcome | −7.1 ± 0.4 | −6.7 ± 0.5 |
Change in depression
- Clinically meaningful improvements in depression in both groups, with no significant differences between the groups
Safety
Psychiatric adverse events
Depressive symptom increases
Suicidal ideation
Psychiatric adverse events
- NB-ER and placebo did not differ
Depressive symptom increases
- NB-ER and placebo did not differ
Suicidal ideation
- NB-ER and placebo did not differ
Original publication
Use of Naltrexone–Bupropion in Persons With Overweight/Obesity and Symptoms of Depression: A Pooled Analysis. Obesity (Silver Spring). Published 31 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →